BioNTech (BNTX) is trading higher as the market digests newly discussed Phase 2 efficacy metrics for pumitamig (an oncology antibody program partnered with Bristol Myers Squibb), following data presented at the European Lung Cancer Congress 2026. Investors are treating the update as incremental de-risking ahead of pivotal studies, helping the shares rebound from levels near the low end of the recent trading range.      (ng.investing.com)

In extensive-stage small cell lung cancer, pumitamig plus chemotherapy in a China dataset reported an 82% confirmed overall response rate, with median progression-free survival of 6.93 months and median overall survival of 16.85 months; the figures were framed as broadly consistent with outcomes seen in a global Phase 2 dataset. In first-line non-small cell lung cancer, a 20mg/kg monotherapy cohort reported a 46.7% confirmed overall response rate, median progression-free survival of 13.6 months, and median overall survival of 27 months, with higher PD-L1 expression associated with longer progression-free survival. (ng.investing.com)

An H.C. Wainwright note cut its price target to $130 from $140 while keeping a Buy rating, but the narrative for traders is that Phase 2 signals reduce uncertainty ahead of Phase 3 readouts (ROSETTA Lung-01 and ROSETTA Lung-02). In parallel, BioNTech has reiterated that 2026 is set up for multiple pipeline readouts and is leaning on a strong liquidity position to fund late-stage development, which can provide a valuation backstop when sentiment improves around clinical risk. (ng.investing.com)

Near term, investors will monitor any additional sell-side revisions tied to the lung-cancer program and how management frames timing and enrollment progress for the ROSETTA Phase 3 trials. On the fundamental calendar, the next major company update is BioNTech’s first-quarter 2026 financial results and corporate update on May 5, 2026, a potential checkpoint for 2026 guidance, burn rate, and pipeline milestones. (investors.biontech.de)